# Amar Gajjar

Source: https://onco.cc/people/amar-gajjar/  
OnCo record `amar-gajjar` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the St. Jude medulloblastoma trials that introduced molecular subgroups into risk-adapted treatment.

## Summary

Amar Gajjar led SJMB96 and SJMB03, the St. Jude medulloblastoma trials that established risk-adapted craniospinal radiotherapy with dose-intensive chemotherapy and showed how WNT, SHH and group 3/4 subgroups predict outcome, and SJMB12, the first trial to assign treatment by molecular subgroup. He co-chairs the Children's Oncology Group CNS committee and directs neuro-oncology at St. Jude.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: paediatric; medulloblastoma; st-jude
- Role: Chair, Department of Pediatric Medicine, St. Jude Children's Research Hospital
- Specialisms: Medulloblastoma; Paediatric neuro-oncology; Risk-adapted therapy; Molecular stratification

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Gajjar%20A%5BAuthor%5D%20medulloblastoma

## Connected records

- cancers: [Medulloblastoma](https://onco.cc/cancers/medulloblastoma/)
- technologies: [DNA methylation profiling](https://onco.cc/technologies/methylation-profiling/), [Proton therapy](https://onco.cc/technologies/proton-therapy/)
- institutions: [St. Jude Children's Research Hospital](https://onco.cc/institutions/st-jude/)

---
JSON: https://onco.cc/api/v1/entities/amar-gajjar.json